Oral small-molecule tyrosine kinase 2 and phosphodiesterase 4 inhibitors in plaque psoriasis: a network meta-analysis

BACKGROUND: Orally administered small-molecule drugs including tyrosine kinase 2 (TYK2) inhibitors and phosphodiesterase 4 (PDE4) inhibitors are new candidates for systemic therapy in plaque psoriasis. However, no previous articles evaluated the benefit and risk profile of TYK2 and PDE4 inhibitors i...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yuanyuan, Li, Zhixuan, Wu, Shuwei, Guo, Linghong, Jiang, Xian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272578/
https://www.ncbi.nlm.nih.gov/pubmed/37334353
http://dx.doi.org/10.3389/fimmu.2023.1180170

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272578/
https://www.ncbi.nlm.nih.gov/pubmed/37334353
http://dx.doi.org/10.3389/fimmu.2023.1180170

Ejemplares similares